Conforming to the IPEC CoA Guide - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Conforming to the IPEC CoA Guide
Past IPEC-Americas excipient qualification committee chairs highlight changes to the IPEC guide on certificates of analysis for bulk excipients.


Pharmaceutical Technology
Volume 37, Issue 3, pp. 28-31

References

1. D. Schoneker, Changing the Supply-Chain Controls for Excipients –Part I: The IPEC-Americas Certificate of Analysis Guide for Bulk Pharmaceutical Excipients, Pharm.Tech. (June 2000).

2. IPEC-Americas, Excipient Master File Guide (2004), http://ipecamericas.org/.

3. IPEC-Americas and IPEC Europe, Excipient Pedigree Position Paper (2009), http://ipecamericas.org/.

4. IPEC-Americas and IPEC Europe, Excipient Stability Program Guide (2010), http://ipecamericas.org/.

5. IPEC-Americas and IPEC Europe, Good Distribution Practices Guide (2006), http://ipecamericas.org/.

6. IPEC-Americas, Good Distribution Practices Audit Guide (2011), http://ipecamericas.org/.

7. IPEC-Americas, IPEC Europe, and the PQG, Good Manufacturing Practices Audit Guide (2007), http://ipecamericas.org/.

8. IPEC-Americas, IPEC Europe, and the PQG, Good Manufacturing Practices Guide (2006), http://ipecamericas.org/.

9. IPEC-Americas and IPEC Europe, Qualification of Excipients for Use in Pharmaceuticals (2008), http://ipecamericas.org/.

10. IPEC-Americas and IPEC Europe, Quality Agreement Guide and Template (2009), http://ipecamericas.org/.

11. IPEC-Americas, Significant Change Guide (2009), http://ipecamericas.org/.

12. IPEC, International Pharmaceutical Excipient Council Glossary (2010), http://ipecamericas.org/.

13. A. Falk, PhD, Pharm.Tech. 34(3) (Mar. 2010).

14. B. Carlin et al., Pharm. Tech. 31 (9) (Sept. 2007).

15. PQG PS 9100:2002 Annex C Certificates of Analysis; WHO Technical Report Series, No. 902 & No. 908; UK Guidance on Certificates of Analysis (from Orange Guide).

16. Note: It is hoped that in the future, all excipient makers and excipient users will realize the benefits of establishing a long-term confidential disclosure agreement during the supplier qualification process.

17. USP, USP 35 General Notices, 5.40 Identity

18. 21 CFR 211.84(d)1

19. EU Legislation–Eudralex Vol 4: Good Manufacturing Practice Guidelines, Chapter 6 Quality Control, Annex 8 Sampling of Starting and Packaging Materials (2006).

Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect that of their employers.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here